Bladder Cancer

The FDA has granted a priority review to a biologics license application for durvalumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed on standard platinum‑based chemotherapy.

Gopa Iyer, MD, discusses the standard chemotherapy options available for patients with bladder cancer, the ongoing progress with immunotherapy, and the management of immune-related toxicities.

Dean Bajorin, MD, discusses the ongoing studies exploring new chemotherapy approaches in these patients and how the cytotoxic treatments could still ultimately be replaced with immuno-oncology agents.

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses studies evaluating second-line treatment options in bladder cancer.

Novel immunotherapy agents continue to move through the pipeline in the treatment landscape of bladder cancer, and they show no signs of slowing down.

Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy induced an 80% complete remission rate among children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia.

Deepak A. Kapoor, MD, Chairman and CEO of Integrated Medical Professionals, discusses how physicians can adapt to the new value-based payment models.

Renowned oncologist Charles G. Drake, MD, PhD, has joined NewYork-Pesbyterian/Columbia University Medical Center (CUMC).

The FDA has issued a complete response letter to&nbsp;Spectrum Pharmaceuticals for apaziquone (EOquin; Qapzola) in bladder cancer.&nbsp;<br /> &nbsp;

Joaquim Bellmunt, MD, PhD, attending physician of Solid Tumor Oncology at Dana-Farber Cancer Institute, discusses the impact of the phase III KEYNOTE-045 study, which compared second- or third-line pembrolizumab with investigator-choice chemotherapy as a treatment for patients with metastatic or locally advanced, unresectable urothelial carcinoma. All patients in the study had recurred or progressed following platinum-based chemotherapy.

Treatment with the combination of nivolumab and ipilimumab at selected doses led to a high response rate and marked improvements in overall survival ​for patients with pretreated metastatic urothelial carcinoma.

Treatment with pembrolizumab improved overall survival by 2.9 months compared with chemotherapy for patients with advanced urothelial carcinoma whose disease progressed after prior treatment.

The recommendation for molecular testing made in the&nbsp;second revision of the 2016 guidelines on bladder cancer&nbsp;from the National Comprehensive Cancer Network (NCCN)&nbsp;could&nbsp;make a considerable difference in increasing the amount of trials&nbsp;and targeted therapies in the long run for subtypes of patients&nbsp;with bladder cancer.

Early results from a pre-planned interim analysis in the KEYNOTE-052 phase II trial of first-line pembrolizumab in cisplatin-ineligible patients with metastatic urothelial cancer demonstrated antitumor activity.

First-line pembrolizumab demonstrated significant antitumor activity in cisplatin-ineligible patients with metastatic urothelial cancer.

Arjun Balar, MD, assistant professor of medicine, Division of Hematology &amp; Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the results of a recent first-line study of pembrolizumab in advanced urothelial cancer.

Findings of the phase III KEYNOTE-045 trial showed pembrolizumab (Keytruda) demonstrated improved survival compared with chemotherapy in previously treated patients with advanced urothelial cancer.

Nivolumab (Opdivo) has received a priority review designation from the FDA as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma.

Matthew Galsky, MD, professor of Medicine, Mount Sinai School of Medicine, discusses the significant findings in, and the rationale behind conducting the CheckMate-275 trial during an interview at the 2016 ESMO Congress.

Safety, efficacy, and biomarker results from the phase II CheckMate-275 trial of the PD-1 inhibitor nivolumab (Opdivo) that support FDA and European Medicines Agency (EMA) applications were reported at the 2016 ESMO Congress.

Jim Zhong, MD, and colleagues describe a National Cancer Database (NCDB) outcomes analysis of patients with muscle invasive bladder cancer treated with either radical surgery or bladder preservation therapy.

Gary D. Steinberg, MD, discusses how medical oncologists can benefit from the new American Urological Association guidelines when treating bladder cancer.

In a 14-0 vote, the FDA&rsquo;s Oncologic Drugs Advisory Committee (ODAC) denied the approval of apaziquone (EOquin; Qapzola) for intravesical instillation immediately following transurethral resection in patients with non-muscle invasive bladder cancer.

A type II variation application for the use of nivolumab (Opdivo) as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma (mUC) who have progressed following platinum-based chemotherapy is now under formal review.

Though the current standard of care when treating muscle-invasive bladder cancer calls for neoadjuvant chemotherapy followed by radical cystectomy, the procedure is associated with a fair amount of morbidity and is not suggested lightly, according to Stanley Yap, MD.

Cell cycle progression (CCP) and homologous recombination deficiency (HRD) may be linked to bladder cancer recurrences and pathologic complete responses, according to Hristos Kaimakliotis, MD.

Alexander I. Sankin, MD, assistant professor of Urology at Montefiore Medical Center at the Albert Einstein College of Medicine, discusses the differences between the recently defined checkpoint HHLA2 and PD-L1 expression in urothelial tumors, as well as next steps in this space.

The field of metastatic bladder cancer&mdash;an area that had long been stagnant&mdash;has quickly evolved with the recent FDA approval of atezolizumab (Tecentriq) coupled with the breakthrough therapy designation of nivolumab (Opdivo).

Across the fields of renal cell carcinoma, bladder cancer, and prostate cancer, immunotherapy agents are moving through the pipeline and impacting patient outcomes&mdash;some quicker than others.

The treatment paradigm of metastatic urothelial carcinoma was shaken up in May 2016 when the FDA approved the PD-L1 inhibitor atezolizumab for the treatment of patients with locally advanced or metastatic disease.